

RESEARCH

Open Access

Prevalence of Metabolic Syndrome and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. *Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 14)*

Rajiv Raman¹, Aditi Gupta¹, Swakshyar S Pal¹, Suganeswari Ganesan¹, Kadri Venkatesh¹,
Vaitheeswaran Kulothungan², Tarun Sharma^{1*}

Abstract

Background: The Metabolic syndrome (MS) consists of central obesity, glucose intolerance, hyperinsulinemia, low high density lipoproteins, high triglycerides and hypertension. Different studies have observed that MS causes microvascular complications in patients with type 2 diabetes. The aim of the study was to find out the prevalence of MS in the Indian population with type 2 diabetes mellitus in relation to gender, duration of diabetes, and to evaluate the influence of MS and its individual components on microvascular complications such as diabetic retinopathy, diabetic nephropathy and diabetic neuropathy.

Methods: A population-based cross sectional survey was conducted with 1414 patients having type 2 diabetes mellitus. The International Diabetes Federation (IDF) criteria were used to identify the metabolic syndrome. Diabetic retinopathy was graded using the stereoscopic digital fundus photography. Neuropathy was assessed by measuring the vibration perception threshold through a sensitometer. Nephropathy was diagnosed by the presence of microalbuminuria in the first morning urine sample.

Results: The age and gender adjusted prevalence of MS, using the IDF criteria, in the South Indian population was 73.3%. The prevalence was higher in women (83.3%), compared to men (65.3%). In subjects with diabetes mellitus, without and with MS, the prevalence of retinopathy was 21.3% and 16.9% ($p = 0.057$); prevalence of nephropathy was 20.5% and 18.0% ($p = 0.296$), and prevalence of neuropathy was 17.2% and 19.4% ($p = 0.353$) respectively. Overall and in women, the clustering of MS components led to an increase in the prevalence of diabetic nephropathy. The prevalence of retinopathy and neuropathy in MS subjects, who had diabetes for < 10 years, was more in both men and women; it was more in women but not in men when the duration of diabetes varied from 11-20 years.

Conclusions: The association of MS with microangiopathies decreased with an increase in the duration of diabetes. MS behaved differently in men and women. It may need to be managed differently in the two groups.

* Correspondence: drtaruns@gmail.com

¹Shri Bhagwan Mahavir Vitreoretinal Services, 18, College Road, Sankara Nethralaya, Chennai-600 006, Tamil Nadu, India
Full list of author information is available at the end of the article

Background

The Metabolic Syndrome (MS) is a constellation of central obesity, glucose intolerance, hyperinsulinemia, low high density lipoproteins (HDL), high triglycerides and hypertension [1]. It is associated with a high risk of coronary heart disease (CHD) and premature mortality [2]. Besides resulting in macrovascular complications, there is growing evidence that MS, like diabetes mellitus, causes microvascular complications in patients with type 2 diabetes mellitus [3-5]. Nearly 70-80% of the population with diabetes mellitus is diagnosed with MS [6-8].

The correlation between MS and macro- and microvascular complications, in patients with diabetes mellitus, has been shown previously in American and European subjects [9-11]. The data in the Asian population is scanty and controversial. In Japan, the Funagata Study observed that MS, using the definition of the International Diabetes Federation (IDF), was associated with microvascular changes in the retina [12]. However, Terauchi *et al* [13] found that neither the presence of MS (as defined by the IDF guideline) nor an increased waist circumference increased the risk of micro- or macrovascular complications in Japanese patients with type 2 diabetes mellitus.

The Asian population is somewhat different from the Caucasian population. The incidence of CHD and the absolute risk of death from CHD, at the same level of blood pressure, is lower in Asians, more so in populations with diabetes [14,15]. The prevalence of obesity and its impact on cardiovascular disease is also different in Asians, compared to Caucasians [16].

The present population-based study aims to find out the prevalence of MS in the Indian population with type 2 diabetes mellitus in relation to gender, duration of diabetes, and to evaluate the influence of MS and its individual components on microvascular complications such as diabetic retinopathy (DR), diabetic nephropathy and diabetic neuropathy.

Methods

The sample population was recruited from the SN-DREAMS 1 study which was a population-based cross-sectional study. The methodology has been described elsewhere [17]. The study population was selected by multistage systematic random sampling. The sampling was done in two stages: selection of divisions using computer generated random numbers, and selection of study subjects randomly from each selected division. A target sample size was calculated based on the following assumptions: the prevalence of diabetic retinopathy was assumed to be 1.3%, with a relative precision of 25%, a drop out rate of 20% and a design effect of 2. The sampling was stratified based on the socio-economic criteria. Ten divisions were selected and 600 individuals were

enumerated from each division to meet the target. Thus, 5830 subjects from the general population aged ≥ 40 years were enumerated.

Of the 5830 subjects enumerated, 1414 subjects with diabetes (both known and newly diagnosed) were analyzed for the study (the response rate for the first fasting blood sugar estimation was 96.20%; the response rate for the base hospital examination was 85.60%; 8.7% were non-diabetic, after the second blood sugar estimation, and 0.78% retinal images were un-gradable). Subjects with diabetes were identified based on the American Diabetes Association criteria and they underwent a detailed examination at the base hospital [18].

After eight hours of overnight fasting, the fasting blood sample was taken to estimate the plasma glucose and serum lipids. For those with provisional diabetes, confirmation of diabetes was done by re-estimation of fasting blood glucose by enzymatic assay; glucose was oxidized by glucose oxidase to produce gluconate and hydrogen peroxide, which was then detected photometrically. A biochemical analysis was done on Merck Micro Lab 120, semi automated analyzer. The total serum cholesterol (CHOD-POD method), HDL (after protein precipitation CHOD-POD method) and serum triglycerides (CHOD-POD) were estimated.

Anthropometric measurements including weight, height, waist and hip measurements were obtained using standardized techniques. The blood pressure was recorded, in the sitting position, in the right arm to the nearest 2 mm Hg using the mercury sphygmomanometer (Diamond Deluxe BP apparatus, Pune, India). Two readings were taken, five minutes apart, and their mean was taken as the blood pressure.

The study was approved by the Institutional Review Board, and a written informed consent was obtained from the subjects as per the Helsinki declaration [19].

Definitions

Metabolic syndrome

MS was defined using the International Diabetes Federation (IDF) consensus group guidelines as abdominal obesity (waist circumference ≥ 90 cm for men and ≥ 80 cm for women) plus two or more of the following risk factors: blood pressure $\geq 130/85$ mm Hg, fasting plasma glucose ≥ 5.6 mmol/l (100 mg/dl) or pre-existing diabetes, serum triglycerides ≥ 1.7 mmol/l (≥ 150 mg/l) and HDL levels < 1.03 mmol/l (< 40 mg/dl) for men and < 1.29 mmol/l (< 50 mg/dl) for women [20].

Diabetic Retinopathy

All patients had their fundi photographed using the 45° four-field stereoscopic digital photography. The diagnosis of DR was based on the modified Klein classification (Modified Early Treatment Diabetic Retinopathy Study

scales) [21]. DR was divided into mild, moderate and severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR); clinically significant macular edema (CSME) was graded as absent or present [22]. This grading was done by two independent observers in a masked fashion; the grading agreement was high ($k = 0.83$) [17].

Diabetic Nephropathy

The microalbuminuria was estimated, using the first morning urine sample, by a semi-quantitative procedure (Clintek 50 Bayer Urine Analyzer). Subjects were considered to have microalbuminuria, if the Albumin Creatinine Ratio (ACR) was between 30 and 299 mg/g [23].

Diabetic Neuropathy

Diabetic neuropathy assessment was done by measuring the Vibration Perception Threshold (VPT) using a sensimeter. The VPT was measured, by a single observer, by placing a biothesiometer probe perpendicular to the distal plantar surface of the great toe of both the legs. The VPT was measured at a voltage level when the patient felt the first vibration sensation. The mean VPT measure of the three readings, of both the legs, was considered for the analysis. The presence of diabetic neuropathy was considered if the VPT value was > 20 V [24].

Statistical analysis

A computerized database was created for all the records. A statistical package for the Social Sciences-SPSS (version 9.0) was used for statistical analysis. All the data were expressed as mean \pm S.D or as percentage. The statistical significance was assumed at p value ≤ 0.05 . Univariate and multivariate logistic regression analyses were performed to elucidate the risk factors for microangiopathies. The Odds Ratio (OR), with 95% confidence intervals, was calculated for the studied variables.

Results

The prevalence of MS in our subjects, with type 2 diabetes mellitus, was 73.8% (95% CI 71.5-76.0); the age and gender adjusted prevalence being 73.3% (95% CI 73.2-73.3). The prevalence was higher in women 83.3% (95% CI 80.4-86.1) compared to men 65.3% (95% CI 61.9-68.7). Table 1 shows the prevalence of MS in relation to gender and the duration of diabetes in subjects with type 2 diabetes mellitus. The prevalence of MS in men decreased with an increase in the duration of diabetes (67.4%, 59.7% and 39.1% in duration < 10 years, 10-20 years and > 20 years respectively, trend $p = 0.002$) whereas it remained almost similar in women (83.8%, 79.1% and 81.8%, trend $p = 0.401$).

Table 2 shows the age and gender adjusted prevalence of individual components of MS in subjects with type 2 diabetes mellitus. The prevalence of increased waist circumference was 75.5% (95% CI 75.4-75.6); of

Table 1 Prevalence of Metabolic Syndrome in relation to gender and duration of Diabetes in the study population

Duration of Diabetes (Years)	Prevalence of Metabolic Syndrome			
	n	%	(95% CI)	Trend p
Overall				
0-10 (N = 1194)	901	75.5	[73.0-77.9]	
11-20 (N = 186)	124	66.7	[59.9-73.4]	
> 20 (N = 34)	18	52.9	[36.2-69.7]	0.0002
Total (N = 1414)	1043	73.8	[71.5-76.0]	
Men				
0-10 (N = 608)	410	67.4	[63.7-71.2]	
11-20 (N = 119)	71	59.7	[50.8-68.5]	
> 20 (N = 23)	9	39.1	[19.2-59.1]	0.002
Total (N = 750)	490	65.3	[61.9-68.7]	
Women				
0-10 (N = 586)	491	83.8	[80.8-86.8]	
11-20 (N = 67)	53	79.1	[69.4-88.8]	
> 20 (N = 11)	9	81.8	[59.0-104.6]	0.401
Total (N = 664)	553	83.3	[80.4-86.1]	

N, Total population; n, Population with metabolic syndrome.

hypertension, 75.3% (95% CI 75.2-75.3%); of elevated serum triglycerides, 37.5% (95% CI 37.5-37.6); and of reduced serum HDL, 71.3% (95% CI 71.2-71.3%).

Table 3 shows the baseline demographic and laboratory characteristics of the study population. Overall, subjects with MS had a higher serum non HDL cholesterol ($p = 0.029$). However, they had lesser duration of diabetes than those without MS ($p < 0.0001$). On evaluating men and women separately, men with MS showed similar findings except for a raised level of hemoglobin in subjects with MS ($p = 0.013$). But in women with MS, the duration of diabetes and serum non HDL cholesterol were not significantly different ($p = 0.084$ and 0.488 respectively), and the levels of total serum

Table 2 Prevalence of individual components of Metabolic Syndrome

Components	Prevalence of Metabolic Syndrome			
	N	n	% *	[95% of CI]*
Increased Waist circumference	1414	1077	75.5	[75.4-75.6]
Hypertension	1414	1026	75.3	[75.2-75.3]
Elevated serum triglyceride	1414	547	37.5	[37.5-37.6]
Reduced serum HDL-Cholesterol	1414	1026	71.3	[71.2-71.3]

$>N$, Total population; n, Population with metabolic syndrome; Age and gender adjusted.

Table 3 Baseline characteristics of the study population

Variables	Metabolic Syndrome								
	Overall			Men			Women		
	Absent n = 371	Present n = 1043	p	Absent n = 260	Present n = 490	p	Absent n = 111	Present n = 553	p
Age (years)	57.0 ± 10.3	56.1 ± 9.9	0.119	57.1 ± 10.5	56.8 ± 10.5	0.664	56.8 ± 9.8	55.4 ± 9.4	0.181
HbA _{1c} (%)	8.3 ± 2.4	8.2 ± 2.1	0.366	8.3 ± 2.4	8.2 ± 2.1	0.475	8.2 ± 2.6	8.1 ± 2.1	0.687
Duration of diabetes (years)	6.6 ± 7.5	5.1 ± 5.7	< 0.0001	7.1 ± 8.0	5.7 ± 6.0	0.008	5.5 ± 5.6	4.6 ± 5.3	0.084
Total serum cholesterol (mg/dl)	184.5 ± 40.9	187.2 ± 40.7	0.266	178.1 ± 38.4	183.2 ± 38.4	0.081	199.5 ± 42.8	190.8 ± 42.3	0.048
Serum LDL cholesterol (mg/dl)	113.2 ± 35.9	111.8 ± 35.2	0.506	106.8 ± 33.6	106.3 ± 33.8	0.845	128.2 ± 37.2	116.7 ± 35.8	0.002
Serum Non HDL cholesterol (mg/dl)	3.7 ± 1.0	3.8 ± 1.0	0.029	3.6 ± 0.9	3.8 ± 0.9	0.009	3.9 ± 1.0	3.9 ± 1.1	0.488
Hemoglobin (gm/dl)	13.8 ± 1.8	13.8 ± 1.4	0.884	14.2 ± 1.9	14.5 ± 1.4	0.013	12.7 ± 1.3	13.1 ± 1.1	0.003

HbA_{1c} (%), Glycosylated hemoglobin; LDL, Low density lipoprotein; HDL, High-density lipoprotein.

cholesterol and LDL cholesterol were lower when compared to subjects without MS (p = 0.048 and 0.002 respectively). As observed in men, the hemoglobin level was significantly higher in women with MS (p = 0.003).

Table 4 evaluates the effect of MS on the prevalence of microvascular complications of diabetes. In subjects with diabetes mellitus, without and with MS, the prevalence of retinopathy was 21.3% and 16.9% (p = 0.057); prevalence of nephropathy was 20.5% and 18.0% (p = 0.296) and prevalence of neuropathy was 17.2% and 19.4% (p = 0.353) respectively. When evaluated separately, in men and women, the diagnosis of MS was not significantly associated with the presence of microvascular complications in our study population except for a lower prevalence of nephropathy in men with MS (p = 0.029).

Table 5 shows the effect of aggregation of more number of components of MS on the prevalence of microangiopathies. The IDF definition of MS requires central obesity to be the essential criterion. Since our whole study population was diabetic, the presence of diabetes or raised plasma glucose also became an unchangeable criterion in our study cohort. To study the desired outcome, we grouped the patients into three sets, in increasing order of presence of three, four or five

criteria of MS. When patients were grouped in such a way, the prevalence of diabetic retinopathy, overall and in men, was not different. In women, however, the prevalence of retinopathy increased with a rise in the number of MS components (12.6%, 20.1% and 16.4%, trend p = 0.193 overall; 17.5%, 22.8% and 21.6%, trend p = 0.779 in men; 6.5%, 18.0% and 15.0%, trend p = 0.049 in women). Overall and in women, the clustering of MS components led to an increase in the prevalence of diabetic nephropathy. However, there was no such trend in men (13.9%, 18.5% and 21.7%, trend p = 0.013 overall; 11.6%, 19.2% and 26.3%, trend p = 0.001 for women; 15.8%, 17.6% and 15.9%, trend p = 0.945 in men). For diabetic neuropathy, the prevalence was not different overall and in men, but it increased with grouping of MS components in women (21.2%, 16.8% and 21.6%, trend p = 0.929 overall; 26.9%, 17.1% and 19.2%, trend p = 0.077 in men and 14.0%, 16.6% and 23.6%, trend p = 0.003 in women).

Table 6 shows the influence the duration of diabetes has on the prevalence of microangiopathies in patients with and without MS. The prevalence of retinopathy and neuropathy in MS subjects, who had diabetes for < 10 years, was more in both men and women; it was more in women but not in men when the duration of

Table 4 Comparison of prevalence of microangiopathies in the study population with and without Metabolic Syndrome

Metabolic Syndrome	Diabetic Retinopathy, n = 255	p	Diabetic Nephropathy, n = 264	p	Diabetic Neuropathy, n = 264	p
Overall						
Absent (n = 371)	79 (21.3)	0.057	76 (20.5)	0.296	63 (17.2)	0.353
Present (n = 1043)	176 (16.9)		188 (18.0)		201 (19.4)	
Men						
Absent (n = 260)	61 (23.5)	0.241	60 (23.1)	0.029	46 (17.9)	0.304
Present (n = 490)	97 (19.8)		81 (16.5)		103 (21.1)	
Women						
Absent (n = 111)	18 (16.2)	0.599	16 (14.4)	0.222	17 (15.6)	0.556
Present (n = 553)	79 (14.3)		107 (19.3)		98 (17.9)	

Table 5 Effect of clustering of components of Metabolic Syndrome on microangiopathies

Components of MS	N	Prevalence of Microangiopathies								
		Diabetic Retinopathy			Diabetic Nephropathy			Diabetic Neuropathy		
		n	%	Trend <i>p</i>	n	%	Trend <i>p</i>	n	%	Trend <i>p</i>
Overall (n = 1043)										
+ Any one	309	39	12.6		43	13.9		65	21.2	
+Any two	448	90	20.1	0.193	83	18.5	0.013	75	16.8	0.929
+ Any three	286	47	16.4		62	21.7		61	21.6	
Men (n = 490)										
+ Any one	171	30	17.5		27	15.8		46	26.9	
+Any two	193	44	22.8	0.779	34	17.6	0.945	33	17.1	0.077
+ Any three	126	23	18.3		20	15.9		24	19.2	
Women (n = 553)										
+ Any one	138	9	6.5		16	11.6		19	14.0	
+Any two	255	46	18.0	0.049	49	19.2	0.001	42	16.6	0.030
+ Any three	160	24	15.0		42	26.3		37	23.6	

MS, Metabolic Syndrome; MS absent, Diabetes only or Diabetes + Obesity; + Any one, Diabetes + Obesity + Any of hypertension, reduced HDL or elevated triglyceride; + Any two, Diabetes + Obesity + Any two of hypertension, reduced HDL or elevated triglyceride; + Any three, Diabetes + Obesity + All three of hypertension, reduced HDL or elevated triglyceride; N, Total population with metabolic syndrome; n, Population with metabolic syndrome having microangiopathies.

Table 6 Effect of duration of Diabetes on the prevalence of microangiopathies in study population with or without Metabolic Syndrome

Variables	Groups	Prevalence of Microangiopathy					
		Duration (0-10 years)	<i>p</i>	Duration (11-20 years)	<i>p</i>	Duration (> 20 years)	<i>p</i>
Overall							
Retinopathy	MS Absent	48 (28.2)	< 0.0001	25 (34.7)	0.013	6 (46.2)	1.000
	MS Present	122 (71.8)		47 (65.3)		7 (53.8)	
Nephropathy	MS Absent	61 (29.6)	< 0.0001	12 (22.6)	< 0.0001	3 (60.0)	1.000
	MS Present	145 (70.4)		41 (77.4)		2 (40.0)	
Neuropathy	MS Absent	38 (19.9)	< 0.0001	18 (31.0)	0.005	7 (46.7)	1.000
	MS Present	153 (80.1)		40 (69.0)		8 (53.3)	
Men							
Retinopathy	MS Absent	36 (34.3)	0.002	19 (43.2)	0.451	6 (66.7)	0.508
	MS Present	69 (65.7)		25 (56.8)		3 (33.3)	
Nephropathy	MS Absent	46 (43.4)	0.206	11 (36.7)	0.200	3 (60.0)	1.000
	MS Present	60 (56.6)		19 (63.3)		2 (40.0)	
Neuropathy	MS Absent	24 (24.2)	< 0.0001	16 (40.0)	0.268	6 (60.0)	0.754
	MS Present	75 (75.8)		24 (60.0)		4 (40.0)	
Women							
Retinopathy	MS Absent	12 (18.5)	< 0.0001	6 (21.4)	0.004	0 (0.0)	0.125
	MS Present	53 (81.5)		22 (78.6)		4 (100.0)	
Nephropathy	MS Absent	15 (15.0)	< 0.0001	1 (4.3)	< 0.0001	0 (0.0)	NA
	MS Present	85 (85.0)		22 (95.7)		0 (0.0)	
Neuropathy	MS Absent	14 (15.2)	< 0.0001	2 (11.1)	0.001	1 (20.0)	0.375
	MS Present	78 (84.8)		16 (88.9)		4 (80.0)	

MS, Metabolic Syndrome.

diabetes varied from 11-20 years; and when the duration of diabetes was > 20 years, it was not different in men or women when compared to subjects without MS. Nephropathy was more prevalent in women with MS and whose duration of diabetes was < 10 years and 11-20 years but the prevalence was not different when the duration of diabetes was > 20 years.

To evaluate the relation between the presence of diabetic microvascular complications and individual MS components, we performed a multiple logistic regression analysis by adjusting variables such as age, gender, smoking and alcohol (Table 7). The results showed that the independent risk factors for retinopathy were glycosylated hemoglobin - OR 1.16 (95% CI 1.07-1.26) and duration of diabetes - OR 1.13 (95% CI 1.09-1.16). For nephropathy, the risk factors were glycosylated hemoglobin - OR 1.24 (95% CI 1.15-1.34), duration of diabetes - OR 1.04 (95% CI 1.01-1.07) and hypertension - OR 1.80 (95% CI 1.20-2.70). For neuropathy, the independent risk factors came out to be reduced serum HDL cholesterol - OR 1.03 (95% CI 1.01-1.05) and increased waist circumference - OR 1.02 (1.00-1.04).

Discussion

The present study reports an alarmingly high prevalence of MS, using IDF criteria, in subjects with type 2

diabetes mellitus in a population-based study. One of the IDF criteria for MS, the increased fasting plasma glucose ≥ 100 mg/dl or pre-existing diabetes, was present in all of the participants of the study; therefore, the "metabolic syndrome" in this study is not exactly the same as MS in general sense. In our cohort, almost every three out of four subjects with type 2 diabetes had MS. A similar high prevalence was reported by Surana *et al* [25] in urban Indian population with type 2 diabetes (77.2%) and by Foucan *et al* [26] in Indian immigrants in the USA with diabetes (77%). This prevalence of MS in the South Indian population with diabetes is more than two-fold higher than the reported prevalence in the general urban Indian population [27]. Using a similar definition as ours (IDF), Terauchi *et al* [13] and Bonadonna *et al* [11] reported the prevalence of MS to be 58.5% and 77.6% respectively, which was comparable to that observed in our study.

The present study has observed gender-wise differences with respect to prevalence of MS and its influence on microangiopathies. The MS, in the defined population of type II diabetes mellitus, was more prevalent in women than men (Table 1); there was a positive correlation between the number of components of MS and all types of microangiopathies (Table 5) in women. Like our study, Ghani *et al* [28] and Bonadonna *et al* [11]

Table 7 Multiple logistic model for risk factors for microangiopathies

Independent variables	Overall		Men		Women	
	OR (95% CI)	p	OR (95% CI) *	p	OR (95% CI) †	p
Retinopathy						
Glycosylated Hemoglobin	1.16 (1.07-1.26)	< 0.0001	1.14 (1.02-1.28)	0.020	1.19 (1.07-1.34)	0.002
Duration of Diabetes	1.13 (1.09-1.16)	< 0.0001	1.13 (1.08-1.17)	< 0.0001	1.13 (1.08-1.18)	< 0.0001
Hypertension	1.18 (0.80-1.77)	0.392	1.09 (0.65-1.82)	0.746	1.41 (0.74-2.69)	0.297
Elevated serum Triglyceride	1.01 (0.99-1.00)	0.560	1.00 (0.99-1.00)	0.256	1.00 (0.99-1.00)	0.857
Reduced serum HDL-Cholesterol	1.01 (0.99-1.03)	0.254	1.03 (1.00-1.06)	0.038	0.99 (0.97-1.02)	0.618
Increased Waist circumference	0.98 (0.96-1.01)	0.188	0.96 (0.93-0.99)	0.037	1.01 (0.98-1.04)	0.663
Nephropathy						
Glycosylated Hemoglobin	1.24 (1.15-1.34)	< 0.0001	1.19 (1.07-1.34)	0.002	1.27 (1.15-1.39)	< 0.0001
Duration of Diabetes	1.04 (1.01-1.07)	0.008	1.04 (1.00-1.08)	0.052	1.04 (0.99-1.08)	0.076
Hypertension	1.80 (1.20-2.70)	0.004	1.50 (0.86-2.63)	0.155	2.17 (1.19-3.93)	0.011
Elevated serum Triglyceride	1.00 (0.99-1.00)	0.976	0.99 (0.99-1.00)	0.661	1.00 (0.99-1.00)	0.473
Reduced serum HDL-Cholesterol	0.99 (0.98-1.02)	0.857	1.01 (0.98-1.04)	0.612	0.99 (0.97-1.01)	0.450
Increased Waist circumference	1.02 (1.00-1.04)	0.055	1.03 (0.99-1.07)	0.064	1.01 (0.99-1.04)	0.289
Neuropathy						
Glycosylated Hemoglobin	1.05 (0.97-1.14)	0.192	1.08 (0.96-1.21)	0.198	1.03 (0.92-1.15)	0.596
Duration of Diabetes	1.02 (0.99-1.05)	0.181	1.01 (0.97-1.05)	0.653	1.03 (0.98-1.07)	0.215
Hypertension	1.19 (0.80-1.76)	0.384	0.87 (0.51-1.48)	0.607	1.83 (0.98-3.44)	0.059
Elevated serum Triglyceride	1.00 (0.99-1.00)	0.381	1.00 (0.99-1.00)	0.313	1.00 (0.99-1.00)	0.496
Reduced serum HDL-Cholesterol	1.03 (1.01-1.05)	0.001	1.06 (1.03-1.09)	< 0.0001	1.00 (0.98-1.03)	0.806
Increased Waist circumference	1.02 (1.00-1.04)	0.043	1.01 (0.97-1.04)	0.640	1.03 (1.00-1.06)	0.027

* All factors adjusted with age, gender, glycosylated hemoglobin, hemoglobin, socioeconomic status, smoking status and alcohol status.

† All factors adjusted with age, glycosylated hemoglobin, hemoglobin, socioeconomic status, smoking status and alcohol status.

also reported a higher prevalence of MS in women; however Shimajiri *et al* [4] reported a higher prevalence in men. Among the Indian diabetic population, a higher prevalence of MS in women was reported by Surana *et al* [25]. They proposed the cause to be a higher prevalence of low HDL and central obesity in women, which could partially be attributed to the lower cut-off for waist circumference and higher cut-off for HDL in women as compared to men. In our study, we also noted a higher BMI and lower HDL cholesterol in women as compared to men. But the waist circumference was lower in women despite the lower cut-off, which suggests that there are other factors which increase the prevalence of MS in women. Bonadonna *et al* [11] also commented in their study that this trend could be both due to a true biological phenomenon or a suboptimal choice of gender-specific diagnostic thresholds. Because of these gender-wise differences, female gender should become a focus of high risk target-screening, and attempts should be made to normalize each component of MS so as to minimize the risk of microangiopathies.

Shimajiri *et al* [4] reported that the prevalence of MS decreases along with an increase in the duration of diabetes. They suggested the possible reason to be a decreased BMI as a result of medical intervention in the lifestyle of long term diabetic patients. In our study, we noted this trend only in men. We feel that the better accessibility to medical care and more health awareness among men in our country can be a factor responsible for this. Whether there are other biological or hormonal factors playing a role is not known. We also observed different trends in obesity indices in men and women in the same study cohort, which is possibly related to post-menopausal hormonal changes in women [29]. This might also explain the gender differences in the current study.

Similar to our finding, Ghani *et al* [28] also found an association of MS with less duration of diabetes. The occurrence of microangiopathies in diabetes mellitus is influenced by several of the components of the MS; this implies a possible relationship between microangiopathies and MS. The association of MS with microvascular complications of type 2 diabetes i.e. diabetic retinopathy, nephropathy and neuropathy has been studied in many reports [4,9,11,28], They found the increased prevalence of all three complications in patients with diabetes using different definitions of MS. Kawasaki *et al* [12] used the IDF criteria and reported that the associations between MS and retinal microvascular signs appeared mainly driven by the associations with larger waist circumference. Isomaa *et al* [5] reported that MS was strongly associated with microalbuminuria but had little effect on the development of retinopathy and neuropathy. However, a

study in Japanese patients, on the other hand, did not show any statistically significant association of MS with the prevalence of microvascular complications in type 2 diabetes mellitus [13]. They attributed it to possible ethnicity related differences because in Asian population, MS has also been reported to be non predictive of coronary artery disease in contrast to the results in Caucasian population. In our study, we found a similar lack of association between MS and the increased prevalence of microvascular disease.

Some previous studies have reported an increase in the prevalence of microangiopathies when patients were grouped according to the number of MS components [9,28,30]. In men, we found that there was no trend of increase in diabetic microvascular complications with an increase in the MS features. However, in women, there was a statistically significant increase in the prevalence of diabetic microangiopathies with an increase in the MS components.

On evaluating the influence of the duration of diabetes on the prevalence of microangiopathies in patients with MS, we found that there was a significant association between MS and the prevalence of microangiopathies in subjects with type 2 diabetes mellitus in the early course of the disease which disappeared with the increasing duration of diabetes in both men and women. This suggests that MS might have a more significant influence on increasing the prevalence of microvascular disease in recent diabetics, but gradually with increasing duration of diabetes, this influence decreases. One possible explanation for this could be better metabolic control in diabetic patients due to increasing awareness with longer duration of diabetes. We did find this trend in the present study; subjects with longer duration of diabetes (> 20 years) had better metabolic control (FBS < 110 mg %) than those with shorter duration of diabetes (0-10 and 11-20 years). The FBS < 110 mg% was noted in 61.8%, 73.7% and 79.2% of subjects with duration of diabetes mellitus being 0-10 years, 11-20 years and > 20 years, respectively ($p = 0.005$).

We found the risk factors for retinopathy to be glycosylated hemoglobin and duration of diabetes, for nephropathy to be glycosylated hemoglobin, duration of diabetes, hypertension, increased body mass index and increased waist circumference and for neuropathy to be reduced serum HDL cholesterol on multivariate analysis. Different associations have also been reported in previous studies [5,12,13]. We also found an association of waist circumference with nephropathy as was reported by Hanai *et al* [30].

Conclusions

The strength of current study is that it was a population based study that used standardized methods for

evaluation of microvascular complications of diabetes mellitus. However, the causal relationship could not be assessed because of the cross sectional nature of study. The prevalence and risk factors of microangiopathies among subjects with MS may also be influenced by presence of diabetes mellitus.

This study reports the prevalence and risk factors for MS in subjects with type 2 diabetes. The gender differences in the prevalence and the risk factors for MS in the population with diabetes need further confirmation in a larger prospective study.

Acknowledgements

We acknowledge the support of the RD Tata Trust, Mumbai, for this project.

Author details

¹Shri Bhagwan Mahavir Vitreoretinal Services, 18, College Road, Sankara Nethralaya, Chennai-600 006, Tamil Nadu, India. ²Department of Preventive Ophthalmology (Epidemiology and Biostatistics), 18, College Road, Sankara Nethralaya, Chennai-600 006, Tamil Nadu, India.

Authors' contributions

RR participated in acquisition of data and drafting the manuscript. AG and KV participated in writing the manuscript. SSP and SG participated in data collection and analysis. VK performed the statistical analysis. TS participated in study design and gave final approval of the version to be published. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 26 February 2010 Accepted: 11 November 2010

Published: 11 November 2010

References

1. Reaven GM: **Banting lecture 1988. Role of insulin resistance in human disease.** *Diabetes* 1988, **37**:1595-607.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: **Cardiovascular morbidity and mortality associated with the metabolic syndrome.** *Diabetes Care* 2001, **24**:683-9.
3. Szalat A, Raz I: **Metabolic syndrome and microangiopathy.** *Isr Med Assoc J* 2006, **8**:424-5.
4. Shimajiri Y, Tsunoda K, Furuta M, Kadoya Y, Yamada S, Nanjo K, Sanke T: **Prevalence of metabolic syndrome in Japanese type 2 diabetic patients and its significance for chronic vascular complications.** *Diabetes Res Clin Pract* 2008, **79**:310-7.
5. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L: **The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes.** *Diabetologica* 2001, **44**:1148-54.
6. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G, Savorani G, Zocchi D, Melchionda N: **WHO and ATP III proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes.** *Diabet Med* 2004, **21**:383-7.
7. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: **Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.** *Diabetes* 1998, **47**:1643-9.
8. Alexander C, Landsman PB, Teutsch SM, Haffner SM: **Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.** *Diabetes* 2003, **52**:1210-14.
9. Costa LA, Canani LH, Lisboa HRK, Tres GS, Gross JL: **Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes.** *Diabetic Medicine* 2004, **21**:252-5.
10. Kilpatrick ES, Rigby AS, Atkin SL: **Insulin resistance, the metabolic syndrome, and complication risk in type 2 diabetes: double diabetes in the Diabetes Control and Complications Trial.** *Diabetes care* 2007, **30**:707-12.
11. Metascreen Writing Committee, Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A: **The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey.** *Diabetes care* 2006, **29**:2701-07.
12. Kawasaki R, Tielsch JM, Wang JJ, Wong TY, Mitchell P, Tano Y, Tomimaga M, Oizumi T, Daimon M, Kato T, Kawata S, Kayama T, Yamashita H: **The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study.** *Br J Ophthalmol* 2008, **92**:161-6.
13. Iwasaki T, Togashi Y, Ohshige K, Yoneda M, Fujita K, Nakajima A, Terauchi Y: **Neither the presence of metabolic syndrome as defined by the IDF guideline nor an increased waist circumference increased the risk of microvascular or macrovascular complications in Japanese patients with type 2 diabetes.** *Diabetes Res Clin Pract* 2008, **79**:427-32.
14. Van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A: **The relation between blood pressure and mortality due to coronary heart disease among men in different parts of world. Seven Countries Study Research Group.** *N Engl J Med* 2000, **342**:1-8.
15. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M: **Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity.** *Diabetologia* 2001, **44**(Suppl 2):S3-13.
16. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N: **Japan diabetes complication study group. Obesity and type 2 diabetes in Japanese patients.** *Lancet* 2003, **361**:85.
17. Agarwal S, Raman R, Paul PG, Rani PK, Uthra S, Gayathree R, McCarty C, Kumaramanickavel G, Sharma T: **Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS 1): study design and research methodology.** *Ophthalmic Epidemiol* 2005, **12**:143-53.
18. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM, American Diabetes Association: **Tests of glycemia in diabetes.** *Diabetes Care* 2003, **26**(Suppl 1):S106-108.
19. Touitou Y, Portaluppi F, Smolensky MH, Rensing L: **Ethical principles and standards for the conduct of human and animal biological rhythm research.** *Chronobiol Int* 2004, **21**:161-170.
20. International Diabetes Federation: **New IDF worldwide definition of the metabolic syndrome.** *Press Conference 1st International Congress on 'Pre-diabetes' and the Metabolic Syndrome, Berlin, Germany 2005* [http://www.idf.org/].
21. Klein R, Klein BE, Magli YL, Brothers RJ, Meuer SM, Moss SE, Davis MD: **An alternative method of grading diabetic retinopathy.** *Ophthalmology* 1986, **93**:1183-7.
22. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group: **Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.** *Ophthalmology* 2003, **110**:1677-82.
23. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW, American Diabetes Association: **Nephropathy in Diabetes.** *Diabetes Care* 2004, **27**(Suppl 1):S79-S83.
24. Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, Mohan V: **Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55).** *Diabet Med* 2008, **25**:407-12.
25. Surana SP, Shah DB, Gala K, Susheja S, Hoskote SS, Gill N, Joshi SR, Panikar V: **Prevalence of Metabolic Syndrome in An Urban Indian Diabetic Population Using The NCEP ATP III Guidelines.** *J Assoc Physicians India* 2008, **56**:865-8.
26. Foucan L, Deloumeaux J, Donnet JP, Bangou J, Larifla L, Messerchmitt C, Salmi LR, Kangambega P: **Metabolic syndrome components in Indian migrants with type 2 diabetes. A matched comparative study.** *Diabetes Metab* 2006, **32**:337-42.
27. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K: **Prevalence of metabolic syndrome in an Indian urban population.** *Int J Cardiol* 2004, **97**:257-61.

28. Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P: **Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome.** *Isr Med Assoc J* 2006, **8**:378-82.
29. Raman R, Rani PK, Gnanamoorthy P, Sudhir RR, Kumaramanikavel G, Sharma T: **Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8).** *Acta Diabetologica* 2010, **47**:209-15.
30. Hanai K, Babazono T, Iwamoto Y: **Renal manifestations of metabolic syndrome in type 2 diabetes.** *Diabetes Res Clin Pract* 2008, **79**:318-24.

doi:10.1186/1758-5996-2-67

Cite this article as: Raman *et al.*: Prevalence of Metabolic Syndrome and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. *Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 14).* *Diabetology & Metabolic Syndrome* 2010 **2**:67.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

